AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21777737
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with CERTIFECT applied 14 days prior to tick infestation
Trial: 21777737
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with CERTIFECT applied 7 days prior to tick infestation
Trial: 20635778
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for psychosis, focusing on education about symptoms and cognitive models, including collaborative exploration of thoughts and schemas surrounding delusions and hallucinations.
Trial: 10461765
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg)
Trial: 30946207
Drug: Alirocumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75 mg every 2 weeks; increased to 150 mg at Week 12 if LDL-C ≥ 70 mg/dL at Week 8)
Trial: 23330822
Drug: topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical diclofenac + tobramycin
Trial: 23330822
Drug: topical tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: topical tobramycin
Trial: 23330822
Drug: topical naphazoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical naphazoline
Trial: 15017615
Drug: Lumiracoxib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib (800 mg every day)
Trial: 9230275
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of 0.7 mg free folic acid in cereal for 2 months followed by 2.0 mg free folic acid via a tablet for 4 months
Trial: 9230275
Drug: Normal folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal folate and vitamin B12, but homocysteine levels >10 micromol/l
Trial: 8197064
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy program for behaviorally disordered mentally handicapped patients
Trial: 29433545
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation treatment using the GRADIOR programme
Trial: 29433545
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment consisting of GRADIOR and ehcoBUTLER
Trial: 27756783
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of 7 lipid species to a base model (14 traditional risk factors and medications)
Trial: 24831037
Drug: Automated telecommunication-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated telecommunication-based reminders (daily messages via text or voice)
Trial: 22935508
Drug: Oral ulcers
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral ulcers
Trial: 22935508
Drug: 10 or
RxNorm normalized name: K-10 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 or more oral ulcers during 6 months
Trial: 18174609
Drug: High-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose regimen (HD): two cycles of E(90)C(600) every 2 weeks followed by two cycles of E(90)C(3000)Thiotepa(400) every 3 weeks.
Trial: 18174609
Drug: Dose-dense conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense conventional chemotherapy (DD): four cycles of E(90)C(600) followed by three cycles of C(600)M(40)F(600) every 2 weeks.
Trial: 8839500
Drug: Standard diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diet with 10 mg total carotenoids/d for two cycles
Trial: 8098281
Drug: Ibopamine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine (3 x 100 mg/day p.o.)
Trial: 2441736
Drug: PVB chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVB chemotherapy (cisplatin, vinblastine, and bleomycin)
Trial: 29940166
Drug: rAAV2.REP1 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV2.REP1 (0.1 mL containing 10^11 genome particles)
Trial: 31623894
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h)
Trial: 15730542
Drug: DVP delayed-release/sprinkle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DVP delayed-release/sprinkle
Trial: 15730542
Drug: DVP sprinkle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DVP sprinkle formulation
Trial: 15730542
Drug: DVP extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DVP extended-release tablets
Trial: 11085961
Drug: Trained (TR)
RxNorm normalized name: hyoscyamine sulfate Extended Release Oral Tablet [Hyoscyamine TR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trained (TR) group underwent a residential exercise program at 85% of maximum heart rate, consisting of 2 daily sessions 6 times a week for 2 weeks.
Trial: 3926322
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (275 mg each, 3 tablets)
Trial: 3926322
Drug: Ergotamine combination
RxNorm normalized name: ergotamine, combinations excl. psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergotamine combination (2 mg ergotamine tartrate, 91.5 mg caffeine, 50 mg cyclizine chlorhydrate, 1 tablet)
Trial: 3926322
Drug: Ergotamine combination
RxNorm normalized name: ergotamine, combinations excl. psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergotamine combination
Trial: 31079072
Drug: Metformin (n=45)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (n=45)
Trial: 29859789
Drug: Hypofractionated whole-breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated whole-breast radiation therapy (RT)
Trial: 574352
Drug: Soy isolate-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isolate-based formula supplemented with L-methionine
Trial: 19307271
Drug: Repeat prenatal
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat prenatal corticosteroid treatment (weekly betamethasone)
Trial: 15053915
Drug: Panavia Fluoro
RxNorm normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Panavia Fluoro Cement with AD gel (AD/Panavia); bonded with 4‐META/MMA‐TBB resin.
Trial: 9725481
Drug: Manidipine 20
RxNorm normalized name: manidipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manidipine 20 mg tablet administered after a standardized breakfast
Trial: 7848346
Drug: Vita‐Gerin‐Geistlich (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vita‐Gerin‐Geistlich (1 capsule/day)
Trial: 3178294
Drug: Oral breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral breathing during 30-min exposure to approximately 0.4 ppm O3
Trial: 167583
Drug: Neomycin and
RxNorm normalized name: Neomycin and polymyxin B only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin and Polymyxin B combination
Trial: 31289351
Drug: Adjuvant fluorouracil-based
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant fluorouracil-based chemotherapy
Trial: 28296257
Drug: Rituximab (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1,000 mg in 250 ml saline) administered in 2 courses at weeks 0, 2, 24, and 26.
Trial: 28296257
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 ml saline) administered in 2 courses at weeks 0, 2, 24, and 26.
Trial: 21631494
Drug: Sublingual feverfew/ginger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual feverfew/ginger
Trial: 17595032
Drug: Autologous Preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Preparation Rich in Growth Factors (PRGF)
Trial: 12956892
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 5 days
Trial: 12956892
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 10 days
Trial: 12956892
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 15 days
Trial: 10855738
Drug: Trandolapril/verapamil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/verapamil (2 mg/180 mg)
Trial: 9115527
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus a 15‐minute tepid sponge bath
Trial: 1288925
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and moxibustion (warming needle and point injection)
Trial: 2871418
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (200,000 IU capsules distributed twice, 1-3 months and 6 months after baseline)
Trial: 24373754
Drug: 3% sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% sevoflurane for 3 min via face mask with tidal volume of 2.2 ml kg(‐1) (Group 1)
Trial: 24373754
Drug: 3% sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% sevoflurane for 3 min via face mask with tidal volume of 8 ml kg(‐1) (Group 2)
Trial: 24373754
Drug: 3% sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% sevoflurane for 3 min via face mask with tidal volume of 12 ml kg(‐1) (Group 3)
Trial: 22839514
Drug: Quinapril 21.0±5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 21.0±5 mg/day
Trial: 22839514
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate 87.7±7.6 mg/day
Trial: 19165592
Drug: Family-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused cognitive behavioral therapy (FCBT)
Trial: 18254226
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate therapy for 12 months
Trial: 18254226
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate therapy
Trial: 8588791
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose hyoscine
Trial: 8588791
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose hyoscine and pyridostigmine
Trial: 16410483
Drug: Aspirin (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (160 mg per day)
Trial: 30829892
Drug: High-fidelity training
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fidelity training model for dynamic ONSD measurement using ETT cuff volumes of 0.1 mL, 0.2 mL, and 0.3 mL.
Trial: 14674932
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg oral, bedtime)
Trial: 8490637
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cognitive-behavioral treatment and desipramine
Trial: 3829579
Drug: Meptazinol 140
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 140 mg
Trial: 3829579
Drug: Meptazinol 280
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 280 mg
Trial: 3829579
Drug: Meptazinol (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol (therapeutic dose range)
Trial: 27502703
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose of 59.4-60 Gy
Trial: 27502703
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose of 61-69 Gy
Trial: 27502703
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose of ≥70 Gy
Trial: 27502703
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose of 66 Gy
Trial: 27502703
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose of 70 Gy
Trial: 27502703
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose of ≥71 Gy
Trial: 12436219
Drug: Standard twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard twice a week G-CSF prophylaxis
Trial: 9579238
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms oral desmopressin without a meal (Day B)
Trial: 9579238
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms oral desmopressin with a standard meal (Day C)
Trial: 9579238
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms oral desmopressin 1.5 hours after a standard meal (Day D)
Trial: 9579238
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active treatment days (B, C, D)
Trial: 7699968
Drug: Methylprednisolone 20
RxNorm normalized name: methylprednisolone 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 20 mg per day for three days
Trial: 27988297
Drug: Inhaled glutathione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glutathione (GSH) treatment for 6 months
Trial: 23711530
Drug: PCT-guided antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT-guided antibiotic therapy; n = 20
Trial: 21841092
Drug: Patient self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient self-management (PSM) of warfarin therapy
Trial: 21841092
Drug: Physician management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician management of warfarin therapy
Trial: 18555238
Drug: Microdose GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microdose GnRH agonist (GnRH‐a) flare-up protocol
Trial: 15534050
Drug: Correlation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation with proliferative cellular activity, multidrug resistance expression, or receptor status
Trial: 11172833
Drug: Cetrorelix acetate
RxNorm normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix acetate 1 mg
Trial: 11172833
Drug: Cetrorelix acetate
RxNorm normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix acetate 5 mg
Trial: 11172833
Drug: Cetrorelix acetate
RxNorm normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix acetate (1, 3, or 5 mg)
Trial: 30486682
Drug: 1 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/day carvacrol
Trial: 30486682
Drug: 2 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg/day carvacrol
Trial: 23787501
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (600 mg per day for 14 days)
Trial: 18682969
Drug: Timolol-Dorzolamide drops
RxNorm normalized name: dorzolamide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol-Dorzolamide drops twice daily (n = 19)
Trial: 17052779
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) supplementation 0.4 mg daily
Trial: 17052779
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) supplementation 1.0 mg daily
Trial: 17052779
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) supplementation 5.0 mg daily
Trial: 17052779
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) supplementation (pooled subjects with baseline NT‐proBNP > 40 ng/L)
Trial: 11552016
Drug: Long-term immunotherapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term immunotherapy in epsilon4 carriers
Trial: 9722293
Drug: CT+G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT+G‐CSF
Trial: 26919801
Drug: Colchicine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (mean prescribed dose 2.8 mg within the first 24 hours, cumulative dose 6.9 mg over three days)
Trial: 21434379
Drug: Geviskon forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geviskon forte (10 ml, 3 times a day)
Trial: 21434379
Drug: Aluminum-magnesium antacid
RxNorm normalized name: ALUMINUM/MAGNESIUM HYDROXIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum-magnesium antacid (1 sachet, 3 times a day)
Trial: 12914399
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (iodide 150 microgram + Levothyroxine 75 microgram)
Trial: 12914399
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (150 microgram iodide + 75 microgram L-thyroxine)
Trial: 12914399
Drug: Levothyroxine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine monotherapy
Trial: 12914399
Drug: Iodide or
RxNorm normalized name: sodium iodide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodide or combination therapy
Trial: 12914399
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups with adequate controls and adjustment of Levothyroxine dosage
Trial: 12914399
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Levothyroxine and iodide
Trial: 2798990
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg bid)
Trial: 9018517
Drug: Glucose (trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (trial G)
Trial: 1527319
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone dipropionate (164 micrograms, twice a day for 7 days)
Trial: 28870836
Drug: Clinic-based manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-based manual therapy and individual exercise
Trial: 27504562
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antiviral, analgesic, and neurotrophic agents)
Trial: 12542199
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg suppository)
Trial: 20926006
Drug: Antegrade cardioplegic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antegrade cardioplegic infusion via the aortic root and additional cardioplegia via vein or free arterial grafts (group B)
Trial: 20926006
Drug: Antegrade cardioplegic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antegrade cardioplegic infusion only via the aortic root (group A)
Trial: 16096169
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg estradiol (E(2))
Trial: 16096169
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg estradiol (E(2))/3.75 mg nomegestrol acetate (E(2)/NOMAC)
Trial: 16096169
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg estradiol (E(2))/3.75 mg nomegestrol acetate (E(2)/NOMAC) vs 1.5 mg estradiol (E(2))
Trial: 10968237
Drug: Irbesartan (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (3.3 mg/kg body weight daily)
Trial: 6383009
Drug: Protein at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein at a level of 1.5 g/kg desirable weight per day